Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q14444: Variant p.Arg616His

Caprin-1
Gene: CAPRIN1
Feedback?
Variant information Variant position: help 616 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Histidine (H) at position 616 (R616H, p.Arg616His). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (H) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 616 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 709 The length of the canonical sequence.
Location on the sequence: help GFPRSNQPYYNSRGVSRGGS R GARGLMNGYRGPANGFRGGY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         GFPRSNQPYYNSRGVSR--GGSRGA-RGLMNGYRGPANGFRGGY

Mouse                         GFPRSSQPYYNSRGVSR--GGSRGA-RGLMNGYRGPANGFR

Rat                           GFPRSSQPYYNSRGVSR--GGSRGA-RGLMNGYRGPANGFR

Bovine                        GFPRSNQPYYNSRGVSR--GGSRGA-RGLMNGYRGPANGFR

Drosophila                    NRDRDQ----GGRGDERRNGGDRGNYRSRQYGNSSNTNGRN

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 709 Caprin-1
Region 524 – 709 Disordered
Modified residue 625 – 625 Phosphotyrosine; by EPHA4
Modified residue 626 – 626 Omega-N-methylarginine
Modified residue 633 – 633 Omega-N-methylarginine
Modified residue 636 – 636 Phosphotyrosine; by EPHA4
Mutagenesis 608 – 608 R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-612, K-616, K-619, K-626, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis 612 – 612 R -> A. Major reduction in MYC and CCND2 RNA-binding; when associated with A-633 and A-690.
Mutagenesis 612 – 612 R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-616, K-619, K-626, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis 616 – 616 R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-612, K-619, K-626, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis 619 – 619 R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-612, K-616, K-626, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis 626 – 626 R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-612, K-616, K-619, K-633, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.
Mutagenesis 633 – 633 R -> A. Major reduction in MYC and CCND2 RNA-binding; when associated with A-612 and A-690.
Mutagenesis 633 – 633 R -> K. Abolished ability to undergo liquid-liquid phase separation for the formation of a membraneless compartment; when associated with K-608, K-612, K-616, K-619, K-626, K-640, K-660, K-667, K-676, K-684, K-688, K-690, K-695 and K-698.



Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.